In addition, biomarkers such as PD-L1 or IFN-γ appear to indicate the presence of an active antitumor immune response that could be further enhanced by 4-1BB-targeted therapy, and patients with high levels of tumor IFN-γ may then demonstrate a higher response rate. This evidence concerns the gene CD274 and neoplasm.